Skip to main content
MedinCell S.A. logo

MedinCell S.A. — Investor Relations & Filings

Ticker · MEDCL ISIN · FR0004065605 LEI · 969500R79U6PXCL2FF46 PA Manufacturing
Open in API
Filings indexed 522 across all filing types
Latest filing 2023-02-07 Declaration of Voting R…
Country FR France
Listing PA MEDCL

About MedinCell S.A.

https://www.medincell.com/en/

MedinCell S.A. is a pharmaceutical company at the commercial stage that specializes in the development of long-acting injectable (LAI) therapies. The company's core is its proprietary BEPO® technology platform, which enables the controlled and sustained release of active pharmaceutical ingredients over periods ranging from days to months after a single injection. This technology forms a fully biodegradable depot in situ, designed to improve treatment efficiency, enhance patient compliance, and increase the global accessibility of medicines. MedinCell develops a portfolio of LAI products across various therapeutic areas, including psychiatry, advancing its pipeline through both internal research and strategic partnerships with other pharmaceutical organizations.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is titled "Information mensuelle relative au nombre d'actions composant le capital social et au nombre total des droits de vote" (Monthly information relating to the number of shares comprising the share capital and the total number of voting rights), dated February 7, 2023, and references Article 223-16 of the AMF General Regulation. It explicitly provides a table showing the total number of shares and voting rights as of January 31. This type of regular disclosure concerning the total share capital and voting rights is a specific regulatory filing requirement, often related to major shareholding notifications or capital structure updates, but the most precise fit among the provided codes for a routine monthly disclosure of total shares/voting rights is often captured under general regulatory updates or share capital changes. Since it details the total number of shares and voting rights, it directly relates to the company's capital structure. While 'MRQ' (Major Shareholding Notification) deals with changes in ownership thresholds, this document reports the absolute total, which is a fundamental capital structure disclosure. Given the options, 'SHA' (Share Issue/Capital Change) is a strong candidate as it relates to the capital structure, but 'MRQ' (Major Shareholding Notification) is often used for filings related to the total share count that underpins threshold calculations. However, a direct monthly report on the total share count and voting rights, as mandated by AMF rules, is a specific regulatory disclosure. Since it is a formal, periodic disclosure about the capital base, and not a general announcement of a transaction (POS) or a major shareholder crossing a threshold (MRQ), it fits best as a specific regulatory filing. Given the options, and recognizing this is a mandatory disclosure about the capital base, 'MRQ' is often used broadly for filings concerning the total share count used for threshold calculations, or 'RNS' as a fallback. Looking closely at the definitions, 'MRQ' is for *changes* in significant ownership levels. This document reports the *total* count. 'SHA' is for *new* share issues/splits. Since this is a routine monthly update on the total capital base required by the regulator, and it doesn't fit perfectly into the transaction/event-based codes, 'RNS' (Regulatory Filings - fallback) is appropriate, but let's re-evaluate if it fits 'MRQ'. In many jurisdictions, the filing that reports the total number of shares outstanding (which is used to calculate major shareholdings) is grouped with major holding reports. Given the context of AMF rules regarding voting rights, this is a fundamental capital structure disclosure. If we must choose a specific one, 'MRQ' relates to the denominator used for major holdings. If it were a general announcement, 'RNS' would be used. Since it is a specific, mandated report on the capital structure components, and 'SHA' is for *new* issues, 'MRQ' is the closest fit related to the share base used for ownership reporting, although it is a routine report rather than a notification of a specific crossing event. Given the highly specific nature of the data (total shares and voting rights), and the lack of a dedicated 'Capital Structure Disclosure' code, 'RNS' (Regulatory Filings) is the safest and most accurate fallback for a routine, mandated disclosure that doesn't fit the transactional codes (SHA, POS, DIV, etc.). I will classify it as RNS as it is a routine regulatory filing not covered by the specific event codes.
2023-02-07 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release dated January 24, 2023, announcing the initiation of a Phase 3 study for a new long-acting injectable antipsychotic (mdc-TJK) developed using MedinCell's technology. It details clinical trial progress, partnership with Teva, and future pipeline expectations. This type of announcement, focusing on clinical development milestones, regulatory progress, and pipeline updates, is characteristic of general corporate news releases that do not fit the specific financial reporting categories (like 10-K, ER, IR) or specific corporate actions (like DIV, SHA, DIRS). Since it is a general announcement about business operations and development, and it is not a transcript (CT), a formal financial report (IR, 10-K), or a specific regulatory filing like insider trading or dividend notice, the most appropriate general category is Regulatory Filings (RNS), which serves as a broad category for miscellaneous corporate announcements not covered elsewhere.
2023-01-24 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 90% confidence The document is a press release dated January 24, 2023, announcing the start of a Phase 3 study for a long-acting injectable antipsychotic (mdc-TJK) and providing updates on other pipeline products and regulatory milestones (like the expected FDA approval for mdc-IRM in H1 2023). This content focuses on clinical development, partnerships (Teva), and pipeline progress, which is typical for investor relations communications. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed management discussion (MDA). Since it is an announcement detailing business and clinical progress aimed at investors, it best fits the general 'Investor Presentation' (IP) category if it were a presentation, but given the format is a press release detailing operational and clinical updates, it aligns most closely with general corporate/investor news. However, none of the specific codes perfectly capture a general clinical/pipeline update press release. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general corporate announcement that doesn't fit the specific financial report types (10-K, IR, ER) or specific corporate actions (DIV, CAP, MANG). It is a regulatory update regarding clinical trials (mentioning clinicaltrials.gov), but the primary purpose is corporate news dissemination.
2023-01-24 French
Inside Information / Other news releases
Earnings Release Classification · 95% confidence The document is a press release dated January 5, 2023, announcing positive top-line results from the SAIVE clinical study regarding the prevention of Covid-19 infection using ivermectin. It details efficacy endpoints, safety findings, and the next steps for the company's long-acting injectable program. This type of announcement, focusing on immediate financial/operational results (clinical trial outcomes) without being a full quarterly/annual report, a transcript, or a formal regulatory filing like a 10-K, best fits the 'Earnings Release' (ER) category, as clinical trial results often drive investor sentiment similarly to earnings announcements. It is a direct release of key performance indicators/results. H1 2023
2023-01-05 English
Informations privilégiées / Autres communiqués
Earnings Release Classification · 95% confidence The document is a press release dated January 5, 2023, announcing positive results from a clinical study (SAIVE) regarding the efficacy and safety of ivermectin in preventing Covid-19 infection. This type of announcement, detailing key financial or operational results (in this case, clinical trial outcomes which drive future revenue/strategy) immediately following a period of activity, aligns best with an Earnings Release (ER) or a general operational update. Since it is a specific announcement of results rather than a comprehensive quarterly report (IR) or a management discussion (MDA), and it is not a transcript (CT) or a formal regulatory filing like a 10-K, 'ER' (Earnings Release) is the most appropriate classification for a significant operational/clinical milestone announcement. It is not an RPA because it contains the full results and analysis, not just an announcement that a report is forthcoming. FY 2022
2023-01-05 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release announcing that an external entity, TPICAP Midcap, has initiated research coverage on MedinCell's stock, including a recommendation and price target. This type of announcement, which relates to market perception, analyst reports, or general investor information that doesn't fit a specific regulatory filing (like 10-K, ER, or DIV), is best classified as a general Investor Relations (IR) communication or a Regulatory Filing (RNS) if IR is too broad. Since the content is focused on external analyst coverage and general company updates relevant to investors, 'IR' (Interim / Quarterly Report) is not appropriate, nor is it a formal regulatory filing like 10-K or ER. Given the options, 'IR' (Investor Relations) is the closest fit for general investor communications that aren't formal reports or specific corporate actions, although 'RNS' (Regulatory Filings) is often used for miscellaneous announcements. However, based on the provided definitions, this is a general update aimed at investors about market coverage, which aligns best with the spirit of Investor Relations material. Since 'IR' is defined as 'Interim / Quarterly Report', and this is not a financial report, I must re-evaluate. This is an announcement about an analyst report, not the report itself. It is a general corporate announcement. Since there is no specific category for 'Analyst Coverage Announcement', and it is not a formal regulatory filing like 10-K or ER, the most appropriate fallback is 'RNS' (Regulatory Filings / General regulatory announcements) or potentially 'IP' (Investor Presentation) if we stretch the definition, but 'RNS' is the safest fallback for non-standard announcements.
2023-01-05 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.